Teleman Dan Benjamin purchased $20K of NSRX
Teleman Dan Benjamin (Chief Executive Officer) purchased 6,550 shares of Nasus Pharma Ltd (NSRX) at $3.10 on 2026-06-17.
How this was made
The 30-second read
Why it matters
The newest disclosed fact is the CEO’s open-market purchase (6,550 shares at $3.10) reported via Form 4 filed on 2026-06-22.
Market read
Traders may treat the filing as a small sentiment input, but it does not provide new operational or financial guidance.
What to watch
Check whether there were prior insider transactions, whether the CEO has a pattern of buying/selling, and whether any concurrent operational catalysts (trial readouts, financing, FDA/regulatory updates) are pending.
Background
The article is a primary-source SEC Form 4 insider transaction disclosure for Nasus Pharma (NSRX).
Ticker impact
Nasus Pharma CEO Teleman Dan Benjamin filed a Form 4 for an open-market purchase of 6,550 shares at $3.10 on 2026-06-17.
Near-term impact likely limited; any effect should be small and fade unless followed by additional disclosures or operational news.
The filing is a primary-source insider transaction, but it lacks new company fundamentals (no clinical/regulatory/financial datapoints) and the size is relatively modest versus typical market-moving events.
Market effects
Limited read-across for biotech; insider buying signals sentiment but usually doesn’t reset sector expectations without accompanying trial/regulatory updates.
No clear regional spillover implied by a single-company Form 4.
Primarily company-specific; unlikely to affect global biotech risk appetite materially.
Counterpoint
Insider buys can be routine (e.g., liquidity planning) and may not reflect a change in near-term fundamentals; without a 10b5-1 plan, timing could still be discretionary.
Key entities
- issuerNasus Pharma Ltd
Company whose CEO filed the insider transaction (Form 4) disclosed in the article.
- insiderTeleman Dan Benjamin
CEO and officer/director who purchased shares in an open-market transaction.
